Respiratory Drug Delivery is organized by SMi Group Ltd and will be held from Dec 05 - 06, 2019 at Copthorne Tara Hotel London Kensington, London, England, United Kingdom.
With the rising prevalence of respiratory diseases such as Asthma, cystic fibrosis and COPD, this group of diseases are now amongst the leading cause death, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe, yet little work is being done to reduce this high mortality rate.
Opportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However, the unmet medical needs of respiratory disease sufferers remain.
Join us this year as SMi aim to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs, analyzing the success of digital medical devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design.
Who Should Attend:
Directors, principal scientists, senior scientists, associate directors, managing directors, medical directors, pharmaceutical experts, group leaders, inhalation toxicologists of the following departments:
• clinical pharmacology
• respiratory medicine/ science
• respiratory immunology
• pulmonary specialty
• respiratory physiology
Additional details will be posted as soon as they are available.
|Contact No. :||02078276088
+44 (0)20 7827 6000
|Registration Type||Due Date||Price|
|Regular Fee||30 Sep,2019||GBP 1399.00|
|Registration Type||End Date||Price|
|Eary Fee||28 Jun,2019||GBP 1199.00|